Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovarian cancer detection

This article was originally published in The Gray Sheet

Executive Summary

Protein patterns in blood samples are able to detect 100% of Stage I ovarian cancer cases, according to a "fast-track" study published on The Lancet website Feb. 8. Conducted by the National Cancer Institute, FDA and Correlogic Systems, the Bethesda, Maryland-based developer of the Proteome Quest test, the study analyzed 116 blinded blood samples - 50 with cancer and 66 with non-malignant disease. The bioinformatic test correctly identified all 50 cases of ovarian cancer and 63 (95%) control cases. Correlogic is involved in a two-year cooperative research and development agreements with FDA/NCI Clinical Proteomic Program; additional trials are underway at NCI to confirm specificity and sensitivity of the test and access its efficacy as a stand-alone device...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT016096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel